Dr. Cooper takes the helm as Chair, bringing a track record of scaling healthcare businesses to oversee the company's strategic development and governance. She joins the firm at a pivotal moment, with the company aiming to transition its endoscopically delivered therapy from a European market presence to a broader global footprint. Her mandate centers on navigating the complexities of long-term value creation as the company scales its operations.

Craig Richardson enters the board with a focus on health economics and market access. His role is to bridge the gap between clinical innovation and healthcare systems by building the economic evidence necessary for broader reimbursement. His appointment underscores the company's push to engage directly with payers and policymakers, ensuring that its non-surgical obesity and diabetes treatment gains traction within established international healthcare frameworks. CEO Mike Gutteridge noted that these additions are designed to reinforce the company's commercial strategy, replacing outgoing Chair Mark Lerdal with a team specifically tailored to manage the challenges of global medical device adoption.